POSTECH relocated the technology to Novmetaphama, a company listed in the Korea New Exchange (KONEX). Novmetaphama is professional development company that focuses on metabolic diseases including diabetes mellitus, Alzheimer’s disease, and osteoporosis. Through the relocation, Prof. Kim will be going through the process of creating a new medicine to treat diabetes mellitus. He will work with Beyond Research Innovation and the Development for Good Enterprises (BRIDGE) of the Ministry of Education. They will try to increase the value of the technology by reinforcement of patent and export.
저작권자 © 포항공대신문 무단전재 및 재배포 금지